E
Encapsule Medical
Privately-held medical device company focused on minimally invasive breast biopsy and tissue removal technologies
About Encapsule Medical
Encapsule, Inc. operates as a precision medicine company focused on transforming oncology by personalizing cancer therapy. Founded in 2018 by University of Connecticut graduates Armin Rad, Ph.D., Leila Daneshmandi, Ph.D., and Reza Amin, Ph.D., the company was formed based on the founders' technical experience in biomedical and mechanical engineering to improve cancer treatment procedures. Rad and Daneshmandi, with backgrounds in biomedical engineering, and Amin, in mechanical engineering, met during their graduate studies and established the company to leverage their collective expertise.
The core of Encapsule's business is its proprietary "tumor-on-a-chip" system. This technology enables the growth of patient-derived cancer cells in microtumors outside the body. These microtumors are then screened against various chemotherapeutic drugs, allowing oncologists to select the most effective treatment regimen for a specific patient before administration. This process aims to reduce unnecessary and painful treatment cycles, lower overall healthcare costs, and improve patient outcomes. The service provides a report on the patient's therapeutic response profile in under seven days.
The company targets several key client segments. For oncologists and their patients, the platform provides data to personalize treatment, potentially increasing success rates and quality of life. For pharmaceutical companies, Encapsulate offers its platform and a substantial biobank of patient-derived samples for pre-clinical trials, patient stratification, and mechanism studies. This allows for more efficient drug development and the identification of new therapeutic targets.
Encapsule has achieved significant milestones, securing notable grant funding. It was awarded a $1.25 million SBIR Phase II grant from the National Science Foundation to advance its chemotherapy selection platform for pancreatic and colorectal cancers. More recently, in July 2025, the company received a $3.63 million Phase 1 grant from NASA to develop a "Metastasis-on-a-Chip" technology. This project, in partnership with NASA and Space Tango, will leverage microgravity environments on the International Space Station to better understand cancer metastasis.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Aug 2006 | $30M | $120M | Undisclosed | — |
| SERIES B✓Equity / VC | Oct 2004 | $2.9M | $12M | Undisclosed | — |
Growth signals
Latest recorded traffic for Encapsule Medical is 140 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Encapsule Medical in the San Francisco ecosystem
The Encapsule Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Encapsule Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Encapsule Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






